5-Amino-1MQ Dosing Protocol
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor studied for its effects on fat cell metabolism. By inhibiting NNMT, it increases NAD+ and SAM availability, potentially shifting fat cells from storage to energy expenditure.
Key Points
Step-by-Step Guide
Understand the Mechanism
NNMT consumes NAD+ and SAM in methylation reactions. Inhibiting NNMT increases these cofactors, upregulating energy expenditure pathways in adipose tissue and potentially reversing metabolic dysfunction in fat cells.
Research Dosing
Oral doses in the research community typically range from 50-150 mg daily. Some protocols use 50 mg twice daily. Cell culture studies used micromolar concentrations; human-equivalent dosing is not clinically established.
Administration
Taken orally as a capsule, typically in the morning. Some protocols split into twice-daily dosing. No fasting requirement established.
Protocol Duration
Research protocols typically run 4-8 weeks. Effects on metabolic markers may take 2-4 weeks to become measurable. Combine with caloric management for body composition goals.
Monitor Metabolic Markers
Track body composition via DEXA or calipers, fasting metabolic panels, and lipid profiles at baseline and 4-8 week intervals. NAD+ levels can be measured but testing is specialized.
Warnings & Precautions
- !No human clinical trials have been conducted.
- !All dosing is extrapolated from in vitro and animal research.
- !Long-term safety of NNMT inhibition is unknown.
- !Potential effects on other methylation-dependent processes not characterized.
Frequently Asked Questions
How does 5-Amino-1MQ differ from peptide fat loss compounds?
It is a small molecule, not a peptide, working at the enzymatic level on fat cell metabolism. Unlike GLP-1 agonists (appetite suppression) or AOD-9604 (GH fragment), it targets the fundamental metabolic programming of adipose tissue via NNMT.
Can 5-Amino-1MQ be combined with other compounds?
Some research protocols combine it with GLP-1 agonists or exercise regimens. The unique NNMT mechanism does not overlap with incretin or GH pathways, suggesting complementary potential, though no combination studies exist.
Is 5-Amino-1MQ a peptide?
No, it is a small molecule quinolinium compound. It appears in peptide research discussions due to its metabolic applications and availability through similar vendors, but it is chemically distinct from peptides.